Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ondrej Gojis

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Histopathology|September 3, 2009
An unusual triple-negative breast carcinomaSami Shousha, David Peston, Ondrej Gojis, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 26, 2013
Velamentous insertion of the umbilical cord of twin B as a cause of vasa previa in monochorionic diamniotic twinsJosef Zahumensky, Ondrej Gojis, Imrich Kiss, et al.
The Journal of Craniofacial Surgery|November 23, 2006
Guided tissue regeneration, barrier membranes and reconstruction of the cleft maxillary alveolusMarketa Duskova, Eva Leamerova, Bohuslav Sosna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Does ER-betacx really have no clinical importance in tamoxifen-treated breast cancer patients?Carlo Palmieri, Ondrej Gojis, Bharath Rudraraju, et al.
Lancet (London, England)|September 15, 2009
Poor reception?Constantine Alifrangis, Jonny P Harcourt, Ondrej Gojis, et al.
Nature Reviews. Clinical Oncology|December 23, 2009
The role of SRC-3 in human breast cancerOndrej Gojis, Bharath Rudraraju, Mihir Gudi, et al.
Folia Histochemica Et Cytobiologica|November 9, 2013
Expression of selected proteins in breast cancer brain metastasesOndrej Gojis, Martina Kubecova, Jozef Rosina, et al.
Clinical Breast Cancer|June 14, 2011
Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcomeJonathan Krell, Colin R James, Deep Shah, et al.
Clinical Breast Cancer|May 17, 2011
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab eraCarlo Palmieri, Deep Shah, Jonathan Krell, et al.
Oncotarget|September 4, 2015
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancerCarlo Palmieri, Iain Rj Macpherson, Kelvin Yan, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Histopathology|September 3, 2009
An unusual triple-negative breast carcinomaSami Shousha, David Peston, Ondrej Gojis, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 26, 2013
Velamentous insertion of the umbilical cord of twin B as a cause of vasa previa in monochorionic diamniotic twinsJosef Zahumensky, Ondrej Gojis, Imrich Kiss, et al.
The Journal of Craniofacial Surgery|November 23, 2006
Guided tissue regeneration, barrier membranes and reconstruction of the cleft maxillary alveolusMarketa Duskova, Eva Leamerova, Bohuslav Sosna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Does ER-betacx really have no clinical importance in tamoxifen-treated breast cancer patients?Carlo Palmieri, Ondrej Gojis, Bharath Rudraraju, et al.
Lancet (London, England)|September 15, 2009
Poor reception?Constantine Alifrangis, Jonny P Harcourt, Ondrej Gojis, et al.
Nature Reviews. Clinical Oncology|December 23, 2009
The role of SRC-3 in human breast cancerOndrej Gojis, Bharath Rudraraju, Mihir Gudi, et al.
Folia Histochemica Et Cytobiologica|November 9, 2013
Expression of selected proteins in breast cancer brain metastasesOndrej Gojis, Martina Kubecova, Jozef Rosina, et al.
Clinical Breast Cancer|June 14, 2011
Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcomeJonathan Krell, Colin R James, Deep Shah, et al.
Clinical Breast Cancer|May 17, 2011
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab eraCarlo Palmieri, Deep Shah, Jonathan Krell, et al.
Oncotarget|September 4, 2015
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancerCarlo Palmieri, Iain Rj Macpherson, Kelvin Yan, et al.
Pageof 2